Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD.

J Clin Oncol. 2006 Aug 1;24(22):3651-6.

PMID:
16877733
2.

Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors.

Rowinsky EK.

J Clin Oncol. 2006 Jul 1;24(19):2981-4. Epub 2006 Jun 12. No abstract available.

PMID:
16769983
3.

Advances toward an understanding of brainstem gliomas.

Donaldson SS, Laningham F, Fisher PG.

J Clin Oncol. 2006 Mar 10;24(8):1266-72. Review.

PMID:
16525181
4.

Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, Wright J, Lamborn K, Sebti SM, Prados M.

J Clin Oncol. 2005 Sep 20;23(27):6647-56.

PMID:
16170172
5.

ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma.

Gilbertson RJ, Hill DA, Hernan R, Kocak M, Geyer R, Olson J, Gajjar A, Rush L, Hamilton RL, Finkelstein SD, Pollack IF.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3620-4.

6.

Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.

Delmas C, Heliez C, Cohen-Jonathan E, End D, Bonnet J, Favre G, Toulas C.

Int J Cancer. 2002 Jul 1;100(1):43-8.

8.

Ras inhibitors and radiation therapy.

Jones HA, Hahn SM, Bernhard E, McKenna WG.

Semin Radiat Oncol. 2001 Oct;11(4):328-37. Review.

PMID:
11677657
10.

RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors.

Liu Ax, Du W, Liu JP, Jessell TM, Prendergast GC.

Mol Cell Biol. 2000 Aug;20(16):6105-13.

11.

Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects.

Prendergast GC.

Curr Opin Cell Biol. 2000 Apr;12(2):166-73.

PMID:
10712917
12.

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.

Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH.

J Clin Oncol. 2000 Feb;18(4):927-41.

PMID:
10673536
14.

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.

Rowinsky EK, Windle JJ, Von Hoff DD.

J Clin Oncol. 1999 Nov;17(11):3631-52. Review.

PMID:
10550163
15.
16.
17.

Application of signal transduction inhibition as a therapeutic strategy for central nervous system tumors.

Pollack IF, Bredel M, Erff M.

Pediatr Neurosurg. 1998 Nov;29(5):228-44. Review.

PMID:
9917540
18.

Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.

Lebowitz PF, Prendergast GC.

Oncogene. 1998 Sep 17;17(11 Reviews):1439-45. Review.

19.

Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth.

Bredel M, Pollack IF, Freund JM, Hamilton AD, Sebti SM.

Neurosurgery. 1998 Jul;43(1):124-31; discussion 131-2.

PMID:
9657198
20.

Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes.

Bernhard EJ, McKenna WG, Hamilton AD, Sebti SM, Qian Y, Wu JM, Muschel RJ.

Cancer Res. 1998 Apr 15;58(8):1754-61.

Supplemental Content

Support Center